A Variant in the <em>BACH2</em> Gene Is Associated With Susceptibility to Autoimmune Addison\u27s Disease in Humans by Pazderska A et al.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This work is licensed under a Creative Commons Attribution 4.0 International License 
 
 
Newcastle University ePrints - eprint.ncl.ac.uk 
 
Pazderska A, Oftedal BE, Napier CM, Ainsworth HF, Husebye ES, Cordell HJ, 
Pearce SHS, Mitchell AL.  
A Variant in the BACH2 Gene Is Associated With Susceptibility to 
Autoimmune Addison's Disease in Humans.  
Journal of Clinical Endocrinology and Metabolism 2016, 101(11), 3865-3869. 
 
 
Copyright: 
This article has been published under the terms of the Creative Commons Attribution License (CC-BY; 
https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and 
reproduction in any medium, provided the original author and source are credited. Copyright for this 
article is retained by the author(s) 
DOI link to article: 
https://doi.org/10.1210/jc.2016-2368  
Date deposited:   
16/02/2017 
A Variant in the BACH2 Gene Is Associated With
Susceptibility to Autoimmune Addison’s Disease
in Humans
Agnieszka Pazderska, Bergithe E. Oftedal, Catherine M. Napier,
Holly F. Ainsworth, Eystein S. Husebye, Heather J. Cordell, Simon H. S. Pearce,
and Anna L. Mitchell
Institute of Genetic Medicine (A.P., C.M.N., H.F.A., H.J.C., S.H.S.P., A.L.M.), Newcastle University,
Newcastle upon Tyne NE1 3BZ, United Kingdom; Department of Clinical Science (B.E.O., E.S.H.),
University of Bergen, 5021 Bergen, Norway; and Department of Medicine (E.S.H.), Haukeland University
Hospital, 5021 Bergen, Norway
Context:AutoimmuneAddison’s disease (AAD) is a rare but highly heritable condition. The BACH2
protein plays a crucial role in T lymphocyte maturation, and allelic variation in its gene has been
associated with a number of autoimmune conditions.
Objective: We aimed to determine whether alleles of the rs3757247 single nucleotide polymor-
phism (SNP) in the BACH2 gene are associated with AAD.
Design, Setting, and Patients: This case-control association study was performed in two phases
using Taqman chemistry. In the first phase, the rs3757247 SNP was genotyped in 358 UK AAD
subjects and 166 local control subjects. Genotype data were also available from 5154 healthy UK
controls from the Wellcome Trust (WTCCC2) for comparison. In the second phase, the SNP was
genotyped in a validation cohort comprising 317 Norwegian AAD subjects and 365 controls.
Results: The frequency of the minor T allele was significantly higher in subjects with AAD from the
United Kingdom compared to both the local and WTCCC2 control cohorts (58% vs 45 and 48%, re-
spectively) (local controls,P1.1104; odds ratio [OR], 1.68; 95%confidence interval [CI], 1.29–2.18;
WTCCC2 controls, P  1.4  106; OR, 1.44; 95% CI, 1.23–1.69). This finding was replicated in the
Norwegian validation cohort (P .0015; OR, 1.41; 95%CI, 1.14–1.75). Subgroup analysis showed that
this association is present in subjects with both isolated AAD (OR, 1.53; 95% CI, 1.22–1.92) and auto-
immune polyglandular syndrome type 2 (OR, 1.37; 95% CI, 1.12–1.69) in the UK cohort, and with
autoimmune polyglandular syndrome type 2 in the Norwegian cohort (OR, 1.58; 95% CI, 1.22–2.06).
Conclusion:We have demonstrated, for the first time, that allelic variability at the BACH2 locus is
associated with susceptibility to AAD. Given its association with multiple autoimmune conditions,
BACH2 can be considered a “universal” autoimmune susceptibility locus. (J Clin Endocrinol Metab
101: 3865–3869, 2016)
The BACH2 transcription factor (BTB and CNC Ho-mology 1, Basic Leucine Zipper Transcription factor
2) is expressed predominantly in B lymphocytes and plays
a vital role in regulating CD4 T-cell differentiation. Its
functions include repressing effector CD4 T-cell lineages
(Th1, Th2, and Th17), and it is crucial for the formation
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of regulatory T cells (1). It is therefore a key modulator of
inflammation, keeping immune systemactivation in check
and controlling the balance between immunity and toler-
ance. The BACH2 gene is located on chromosome 6q15.
In murine models, disruption of the BACH2 gene results
in mice that are phenotypically normal at birth, but
which develop fatal autoimmune disease in the first
months of life (1). In humans, a number of common
variants in linkage disequilibrium (LD) at the BACH2
locus have been consistently associated with autoim-
mune conditions, including type 1 diabetes (2), celiac
disease (3, 4), autoimmune thyroid disease (5, 6),
Crohn’s disease (7), multiple sclerosis (8), vitiligo (9),
and rheumatoid arthritis (10). Variants in the BACH2
gene have yet to be studied in autoimmune Addison’s
disease (AAD), which is a rare but highly heritable, or-
gan-specific autoimmune conditionwith a prevalence in
the European Caucasian population of 110–220 cases
per million (11, 12).
We aimed to determine whether the intronic single
nucleotide polymorphism (SNP) rs3757247 is associ-
ated with AAD in two independent cohorts from the
United Kingdom and Norway. This SNP was selected
for investigation because it has previously been associ-
ated with type 1 diabetes and generalized vitiligo, with
odds ratios of 1.13 and 1.21 for the T allele conferring
disease susceptibility, respectively (9, 13), and it is in
tight LD (r2  0.93) with SNPs rs11755527 and
rs619192, which have been associated with type 1 di-
abetes (2),andrs72928038,whichhas
been associated with rheumatoid ar-
thritis (10) (Figure 1). In addition, it is
in moderate LD (r2  0.4) with
rs10806425, which has been associ-
ated with celiac disease (3).
Subjects and Methods
This studywas carried outwith approval
of the Leeds East ethics committee (Ref.
05/Q1206/144) and the Regional Com-
mittee for Medical and Health Research
Ethics (Ref. 2013/1504/REK vest).
The UK AAD cohort comprised 365
Caucasian individuals, of whom 285
were female. A diagnosis of AAD was
confirmed by the subjects having either a
low basal cortisol level with a high
ACTH level or a subnormal response to
the short synacthen test (250 mg paren-
teral synthetic ACTH1–24). Patients with
primary adrenal failure due to adrenal
gland infiltration or infection, with sec-
ondary adrenal failure, or with autoim-
mune polyglandular syndrome type 1
(on the clinical grounds of mucocutaneous candidiasis, hypo-
parathyroidism, and/or ectodermal dystrophy) were excluded.
The median age at diagnosis was 39 years (range, 10–83 years).
In 197 (54%) patients, an additional autoimmune condition
(termed autoimmune polyglandular syndrome type 2 [APS2]
was present, whereas 168 (46%) patients had AAD alone
(termed isolatedAAD [iAAD]). For comparison, a localmatched
control cohort comprising 183 individuals was available. In ad-
dition, genotype data from 5159 healthy individuals was avail-
able through the Wellcome Trust Case Control Consortium 2
(WTCCC2), as previously described (14).
We used 330 Norwegian AAD subjects, of whom 215 were
female, and 384matched controls as an independent replication
cohort. The diagnosis of AAD was made using the criteria de-
scribed above.
Genomic DNA was extracted from venous blood for each
subject in the AAD and local control cohorts. The rs3757247
SNP was then genotyped using Taqman chemistry (Life Tech-
nologies, Thermo Fisher Scientific) according to the manufac-
turer’s instructions. Ten percent of the samples were genotyped
in duplicate to ensure accuracy of results. Genotype results were
available for 358 of 365 UKAAD subjects (genotyping call rate,
98%) and for 166 of 183 local UK controls (genotyping call rate,
91%).Genotyping call rates in theNorwegianAADsubjects and
theNorwegian control cohortswere 96% (317 of 330) and 95%
(365 of 384), respectively. Genotypes were checked for Hardy-
Weinberg equilibrium in both control cohorts (threshold P 
.05) before analysis.
Statistical analysis was performed using PLINK, a freely
available association analysis engine (15). A heterogeneity anal-
ysis was performed to compare genotype and allele frequencies
between the UK control cohort and the WTCCC2 controls to
ensure that theywere comparable. Association analysiswas then
Figure 1. Schematic representation of the BACH2 locus and pairwise LD r2 measures between
selected BACH2 SNPs previously associated with autoimmune conditions. At the top of the
figure, a diagrammatic representation of the BACH2 gene is shown. Exons are denoted by boxes,
and intronic sequence by the line. In the lower half of the figure, SNPs previously associated with
autoimmune conditions are identified by their unique rs numbers. The autoimmune diseases
associated with each SNP are shown (AITD, autoimmune thyroid disease; T1DM, type 1 diabetes;
MS, multiple sclerosis; CD, Crohn’s disease), as is the base pair position of each SNP. Arrows
mark the approximate location of each SNP relative to the introns and exons.
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performed between case and control cohorts, followed by a sub-
group analysis comparing genotype and allele frequencies be-
tween the iAAD and APS2 subgroups from the United Kingdom
compared to theWTCCC2 controls, and between the iAAD and
APS2 subgroups from Norway and the Norwegian controls.
Results
The genotype frequencies in the control cohorts were in
Hardy Weinberg equilibrium (P  .05). There was no
significant difference between genotype and allele fre-
quencies between the UK local control cohort and the
WTCCC2 controls (P  .24 and .21, respectively), and
therefore these control cohorts were deemed comparable
(Table 1).
Comparing the UK AAD cohort to the local controls,
the frequency of the TT genotype was higher, whereas the
frequency of the CC genotype was lower in AAD subjects
(P  .0009) (Table 2). The minor T allele accounted for
413 alleles (58%) in the AAD cohort compared to 149
alleles (45%) in the control cohort (P .00011; odds ratio
[OR], 1.68; 95% confidence interval [CI], 1.29–2.18)
(Table 2).
Comparing the AAD cohort to the larger WTCCC2
controls, a similar association was seen. The frequency of
the TT genotype was higher, whereas the frequency of the
CC genotype was lower in AAD cases (P 9.98 107)
(Table 2). The minor T allele accounted for 413 alleles
(58%) in the AAD cohort compared to 4986 (48%) in the
control cohort (P 1.4 106; OR, 1.44; 95%CI, 1.23–
1.69) (Table 2).
The above findings were replicated in an independent
cohort of AAD and control subjects fromNorway. In this
group, theTTgenotypewas found in 83AADcases (26%)
compared to 76 controls (21%),whereas theCCgenotype
was present in 73AADsubjects (23%) and in 127 controls
(35%). A total of 161AAD subjects (51%)were heterozy-
gous compared to 162 controls (44%) (P  .003). The
minor T allele accounted for 327 alleles (52%) in theAAD
cohort and 314 alleles (43%) in the control population
(P  .0015; OR, 1.41; 95% CI, 1.14–1.75) (Table 2).
We conducted a subgroup analysis in the two cohorts
by dividing the cases into those with APS2 and iAAD
(Table 3). In the UKAPS2 cohort, the T allele was present
in221cases (57%)compared to4986controls (48%) (P
.0013;OR, 1.37; 95%CI, 1.12–1.69). Comparing theUK
iAAD subgroup to the WTCCC2 controls (Table 3), a
similar trendwith stronger associationwasobserved,with
the T allele being present in 192 (59%) of the cases com-
pared to 4986 (48%) controls (P  .00018; OR, 1.53;
95% CI, 1.22–1.92). In the Norwegian cohort, in the
APS2 subgroup, the T allele was present in 182 (54%)
cases compared to 314 (43%) controls (P .00049; OR,
1.58; 95% CI, 1.22–2.06). In the iAAD subgroup, there
was nominal association with genotypes (P .04), but no
association was detected with alleles (P  .12) (Table 3).
Discussion
This is the first report of a BACH2 variant being associ-
atedwith susceptibility to AAD. The association observed
in the UK cohort was replicated in an independent cohort
from Norway. BACH2 variants have previously been as-
sociatedwith themore commonautoimmuneendocrinop-
athies, type 1diabetes and autoimmune thyroid disease. In
Table 1. Comparison of Genotype and Allele Frequencies Between the UK Local and WTCCC2 Cohorts
Cohort Call Rate (%)
Genotype Data Allele Data
TT (%) TC (%) CC (%) P Value T (%) C (%) P Value
Local controls 166/183 (91) 36 (22) 77 (46) 53 (32) .24 149 (45) 183 (55) .21
UK WTCCC2 5154/5159 (100%) 1178 (23) 2630 (51) 1346 (26) 4986 (48) 5322 (52)
Table 2. Genotype and Allele Frequencies for the UK and Norwegian AAD and Control Cohorts
Cohort Call Rate (%)
Genotype Data Allele Data
TT (%) TC (%) CC (%) P Value T (%) C (%) P Value OR [95% CI]
UK AAD 358/365 (98) 124 (35) 165 (46) 69 (19) 413 (58) 303 (42)
UK local controls 166/183 (91) 36 (22) 77 (46) 53 (32) 9  104a 149 (45) 183 (55) 1.1  104a 1.68a [1.29–2.18]
UK WTCCC2 5154/5159 (100) 1178 (23) 2630 (51) 1346 (26) 9.98  107b 4986 (48) 5322 (52) 1.40  106b 1.44b [1.23 to 1.69]
Norwegian AAD 317/330 (96) 83 (26) 161 (51) 73 (23) .003c 327 (52) 307 (48) .0015c 1.41c [1.14–1.75]
Norwegian controls 365/384 (95) 76 (21) 162 (44) 127 (35) 314 (43) 416 (57)
a UK AAD vs UK local controls.
b UK AAD vs UK WTCCC2.
c Norwegian AAD vs Norwegian controls.
doi: 10.1210/jc.2016-2368 press.endocrine.org/journal/jcem 3867
this study, the T allele at rs3757247 appears to be con-
ferring a greater risk in AAD compared to type 1 diabetes
and vitiligo (OR, 1.44 and 1.41 in UK and Norwegian
AAD cohorts, respectively; compared to 1.13 in type 1
diabetes and 1.21 in generalized vitiligo). Functional stud-
ies are now required to investigate the precisemechanisms
bywhich variants in theBACH2 gene confer susceptibility
to autoimmune disease.
We have found that the intronic SNP, rs3757247, is
associated with both iAAD and APS2 in the UK cohort,
suggesting that this variant is independently associated
with AAD in the UK population and that the association
observed is not simply due to the fact that this cohort is
enriched for those with additional autoimmune comor-
bidities. In the Norwegian cohort, however, there was as-
sociation with the cohort as a whole, and in the subgroup
analysis, with APS2. This suggests some genetic heteroge-
neity between these two European cohorts as has previ-
ously been reported (16).
To increase thepowerof this study, theUKAADcohort
was compared to the genotype data available from
the WTCCC2 controls. The samples included in the
WTCCC2 were genotyped using a SNP array. To control
for the use of different genotyping platforms and to ensure
that the WTCCC2 results were comparable to those de-
rived from local controls, we compared genotypes and
allele frequencies derived from a local UK control cohort
to those from the WTCCC2 controls. This analysis dem-
onstrated no significant differences between those two
control groups.
How BACH2 variants influence autoimmune disease
susceptibility is not yet understood. However, possible
mechanisms can be proposed on the basis that the BACH2
protein has a number of crucial functions in modulating
inflammation and immunity. The BACH2 protein is
known to play an important role in regulating lymphocyte
differentiation. It has been shown to repress genes that are
important for both Th1 and Th2 lineage differentiation,
includingGATA3. GATA3 is themaster Th2 lineage tran-
scription regulator, and polymorphisms in the GATA3
gene have previously been associated with AAD (16–18).
Indirect evidence, although limited, supports the role of
IFN-, the Th1-derived cytokine, in adrenocortical de-
struction in AAD. The expression of major histocompat-
ibility complex class II molecules on adrenocortical cells
has been shown tobehighly up-regulatedduring the active
phase of AAD; this effect is likely mediated by IFN- (19,
20). In addition, T cells derived from AAD patients dem-
onstrate higher IFN- production after stimulation with
21-hydroxylase comparedwithhealthy controls (21).Our
finding that genetic variability in the BACH2 gene is as-
sociated with susceptibility for AAD further implicates
this immune pathway in the etiopathogenesis of this
condition.
This study has identified that aBACH2 polymorphism
is associated with AAD in two independent European co-
horts. The rs3757247 SNP is a common intronic variant,
has no known functional consequences, and therefore is
not causative of autoimmune disease. It is likely that this
SNP is in LDwith a causative variant located elsewhere in
the locus.
The role of rare variants, with minor allele frequencies
of 0.01, in complex traits has been increasingly recog-
nized (22). A number of rare variants have been reported
in the BACH2 gene, and some of these are predicted to be
potentially deleterious. A review of SNP data available
from the 1000 Genomes project (23), visualized on the
freely available Ensembl genome browser (release 85)
(24), has shown that five rare missense variants at the
BACH2 locus are predicted to be deleterious by both SIFT
andPolyphen analysis. These are located in a 20-kB region
of the BACH2 gene, with three located in exon 7 and one
located in each of exons 8 and 9. These rare missense
variants are located over 250 kB from the intronic SNP
Table 3. Genotype and Allele Frequencies for the UK and Norwegian Subgroup Analysis
Cohort
Genotype Data Allele Data
TT (%) TC (%) CC (%) P Value T (%) C (%) P Value OR [95% CI]
UK iAAD 57 (35) 78 (48) 28 (17) .0005a 192 (59) 134 (41) 1.8  104a 1.53a [1.22–1.92]
UK APS2 67 (34) 87 (45) 41 (21) .0009b 221 (57) 169 (43) 1.3  103b 1.37b [1.12–1.69]
UK WTCCC2 1178 (23) 2630 (51) 1346 (26) 4986 (48) 5322 (52)
Norwegian iAAD 31 (21) 83 (55) 36 (24) .0369c 145 (48) 155 (52) .12c 1.24c [0.95–1.62]
Norwegian APS2 52 (31) 78 (47) 37 (22) .0038d 182 (54) 152 (46) 4.9  104d 1.58d [1.22–2.06]
Norwegian controls 76 (21) 162 (44) 127 (35) 314 (43) 416 (57)
UK iAAD and APS2 are compared to the WTCCC2 cohort, and Norwegian iAAD and APS2 are compared to local controls.
a UK iAAD vs UK WTCCC2.
b UK APS2 vs UK WTCCC2.
c Norwegian iAAD vs controls.
d Norwegian APS2 vs controls.
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analyzed in this study and are not predicted to be in tight
LD with rs3757247. A single-point analysis of the rare
variants in the BACH2 gene in our cohort would be un-
derpowered because of the low copy number of the mi-
nority allele; however, they warrant further investigation.
The exactmechanismbywhichBACH2variants influence
autoimmune disease risk requires further research, and a
systematic analysis of variation in the region is now re-
quired in large cohorts of patients. Our results add to the
growing literature that demonstrates that theBACH2pro-
tein is a crucial regulator of both immune function and
dysfunction. Autoimmune diseases are known to share a
common genetic architecture, with some loci, such as
CTLA4,PTPN22, and theHLA, conferring susceptibility
to multiple autoimmune diseases. The finding of associa-
tion of a BACH2 variant with a further autoimmune con-
dition, AAD, supports the hypothesis that variation in
BACH2may be a permissive immune system factor that is
implicated in many or most organ-specific autoimmune
conditions.
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